Japanese
English
Home
About Us
Message from CEO
Our Mission
Our Business
Corporate Information
Leadership/ Governance
Access
Our Science
PRIME Technology
Application of Our Technology
Pipelines
Our Partners
IR
IR News
Management
Top Message
Corporate Governance
Disclosure Policy
Financial Highlights
IR Library
Financial Results
Presentation Materials
Securities Report
IR Materials
For Shareholders
Stock Overview
General Meeting of Shareholders
Stock Quotations
IR Calendar
IR FAQ
IR Contact
Disclaimer
Careers
Contact Us
Contact Us
Create the Future to Overcome Cancer
News
2024/06/28
Notice of Re-prioritization of In-house Drug Discovery Pipelines and Change in Use of Funds Raised at the Time of Listing
2024/06/24
Return of NIB102 and NIB103 from Takeda
2024/06/12
Noile-Immune’s President & CEO, Koji Tamada, will make a presentation on “Forefront of next-generation immunotherapy: Development and future outlook of CAR-T cell therapy” at “The 44th JBDA Bioventure Forum” (at Nakajima Touichiro memorial hall, the University of Tokyo) on Thursday, June 13, from 17:20 to 18:10.(Detailed in Japanese)
2024/06/04
Presentation at the American Society of Clinical Oncology (ASCO) From The Phase I Clinical Trial of CAR-T Therapy (NIB102) with Noile-Immune Biotech’s PRIME Technology
2024/06/04
Invention of Immunocompetent Cells Expressing Immune Function Regulatory Factors (Patent No. 6561372) Awarded "Future Creative Invention Encouragement Award" at the 2024 National Invention Award
Details